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Abstract 
The production of IgE specific to different viruses (HIV-1, Parvovirus B19, Parainfluenza virus, 
Varicella Zoster Virus), and the ability of IgE anti-HIV-1 to suppress HIV-1 production in vitro, 
strongly suggest an important role for IgE and/or anti viral specific IgE in viral pathogenesis. 
Nevertheless, the presence and persistence of IgE anti-Influenza virus antibodies has not been 
studied. Total serum IgE and specific IgE and IgG anti-Influenza virus antibodies were studied 
in children (N=3) (m/f 14-16 y/o) and adults (N=3) (m/f, 41-49 y/o) 2-20 months after vac-
cination with Influenza virus (Flumist
® or Fluzone
®), as well as in non-vaccinated children 
(N=2). (UniCAP total IgE Fluoroenzymeimmunoassay, ELISA, Immunoblot). We found that 
serum of vaccinated children and adults contained IgE and IgG anti-Influenza virus antibodies 
approaching two years post vaccination. Non-vaccinated children did not make either IgE or 
IgG anti-Influenza antibodies. Similar levels of IL-2, IFN-γ, IL-4, and IL-10 cytokines were 
detected in serum of vaccinated compared with non vaccinated subjects (p>0.05), as well as 
between vaccinated adults compared with vaccinated children and non vaccinated subjects 
(p>0.05). Vaccinated children and adults continue to produce IgE anti-Influenza virus anti-
bodies long term post vaccination. The long term production of IgE anti-Influenza virus an-
tibodies induced by vaccination may contribute to protective immunity against Influenza. 
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INTRODUCTION 
Previous studies in our laboratory have investi-
gated  the  role  of  IgE  and  the  immune  response  to 
specific viruses including: Parvovirus B19 in children 
[1], HIV-1 in HIV-1 seropositive, non progressor pe-
diatric patients [2, 3], Varicella Zoster Virus (VZV) [4, 
5], as well as in both children and adults with a past 
history of chicken pox infection or VZV vaccination 
[6]. Other studies in our laboratory also identified IgE 
anti-  spirochete  antibodies  (B.  Burgdorferi)  and  its 
persistence one year later in serum of lyme-infected 
children [7].  
Studies  in  humans  and  animals  reported  by 
others  have  identified  IgE  anti-virus  antibodies  in 
several viral infections including respiratory syncytial 
virus  (RSV)  [8,  9],  parainfluenza  [10],  HTLV-1  [11], 
Puumala virus [12], HSV-1, HSV-2, and Epstein-Barr Int. J. Med. Sci. 2011, 8 
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virus [13], and blue tongue virus in cattle [14].  
Studies of Grunewald, et al., reported Influenza 
A  virus-specific  IgE  antibodies  in  the  serum  of  in-
fected mice, and showed local anaphylaxis after re-
challenge  with  the  Influenza  A  virus  antigen;  these 
mice developed virus-specific mast cell degranulation 
in  the  skin  [15].  Recent  studies  of  Davidsson,  et  al 
demonstrated  in  healthy  human  subjects,  with  no 
known  allergy,  IgE  responses  against  Influenza  A 
[16]. No anaphylactic reactions were associated with 
vaccination  [16].  However,  serum  IgE  levels  were 
increased  after  Influenza  vaccination,  which  might 
indicate a participation  of IgE in viral defense [16]. 
Earlier  studies  of  Dobber,  et al  also  found  that  IgE 
specific  Influenza  virus  antibodies  were  increased 
after influenza vaccination in mice [17]. Interestingly, 
low  levels  of  total  Influenza  virus-specific  antibody 
secreting  cells  (ASCs)  have  been  reported  in  blood, 
tonsils, and nasal mucosa of non-allergic study sub-
jects that had not been recently vaccinated or natu-
rally infected with Influenza virus [18]. In their earlier 
studies, they found that Influenza virus-specific an-
tibodies  in  the  oral  fluid  (saliva)  consist  mainly  of 
secretory IgA (sIgA) [19].  
This study is the first, to our knowledge, to de-
scribe the long term persistence of IgE anti-Influenza 
virus antibodies in serum of IgE positive and negative 
vaccinated pediatric and adult subjects, approaching 
two years post vaccination. The exact role of IgE in 
Influenza  virus  infection  remains  to  be  elucidated; 
however, the presence of IgE anti Influenza virus an-
tibodies  several  months  post  vaccination  warrants 
further investigation of the biological significance, if 
any, of these antibodies. 
MATERIALS AND METHODS 
Patient specimen description 
Peripheral blood (3 ml total) was obtained from 
both pediatric (N=3) (m/f, 14-16 yrs old) and adult 
(N=3) (m/f, 41-49 yrs old) Caucasian subjects from the 
SUNY  Downstate  Allergy  Clinic,  who  were  both 
atopic and non atopic, with normal (<100 IU/mL) or 
elevated serum IgE levels. Atopic subjects were skin 
prick  positive  (N=2)  for  environmental  (e.g.  mixed 
tree  and  grass,  ragweed,  weeds,  and  dust  mite)  or 
food  allergens.  Exclusion  criteria  included  food  al-
lergy to egg and antibiotics. At the time of study, the 
subjects had not received allergy therapy, and were 
not being treated with any medication. Subjects did 
not have a past history of parasite infection. Approval 
was obtained from the SUNY Downstate Institutional 
Review Board, and the procedures followed were in 
accordance  with  institutional  guidelines  involving 
human subjects.  
Vaccine description 
All adults were vaccinated with Influenza Virus 
Vaccine  Fluzone®  (inactivated  Influenza  Virus  Vac-
cine,  2009-2010  Formula;  Sanofi  Pasteur  Inc.,  Swift-
water,  PA)  and  children  were  vaccinated  with 
Flumist®  (live  attenuated  Influenza  Virus  Vaccine, 
Intranasal,  2009-2010  Formula;  MedImmune,LLC, 
Gaithersburg,  MD).  Each  0.25  mL  dose  of  Fluzone 
vaccine contains 7.5 mcg  of influenza virus hemag-
glutinin (HA) and each 0.5 mL dose contains 15 mcg 
HA  from  each  of  the  following  3  viruses: 
A/Brisbane/59/2007,  IVR-148  (H1N1), 
A/Uruguay/716/2007/,  NYMC  X-175C  (H3N2)  (an 
A/Brisbane/10/2007-like virus), and B/Brisbane/60 
/2008. Each 0.2 mL dose of Flumist intranasal spray 
contains 10 FFU (fluorescent focus units) of live at-
tenuated influenza virus reassortants of each of the 
three  strains  for  the  2009-2010  season: 
A/California/7/2009  (H1N1),  A/Perth/16/2009 
(H3N2), and B/Brisbane/60/2008.  
Time  post  vaccination  for  subjects  was  2-20 
months. Past history of vaccination was confirmed by 
positive immunoblot for IgG anti Influenza virus. (See 
methods below.) 
Total serum IgE 
Blood  was  collected  and  immunoglobulin  (Ig) 
levels (IgE) were detected in serum (Quest Diagnos-
tics,  Inc.  Teterboro,  NJ),  which  was  performed  ac-
cording  to  manufacturer’s  recommendation.  Refer-
ence  range  for  healthy  adult  or  child  serum:  IgE: 
20-100 IU/mL. 
Influenza virus serum antibody detection: Im-
munoblot 
The presence of IgE or IgG anti-Influenza anti-
bodies was determined by immunoblot (dot blot), as 
previously  described  [5,  6].  Briefly,  Influenza  virus 
vaccine Fluzone (5ul) (90 ug/mL protein conc.) was 
pipetted  onto  nitrocellulose  membrane  strips 
(BIO-RAD  Laboratories,  Hercules,  CA)  and  let  dry. 
Nitrocellulose  membrane  was  then  soaked  in  a  5% 
milk powder (Immunetics Inc., Boston, MA) solution 
(Tween  20  (0.05%  Tween20  (Sigma)  in  tris  buffered 
saline (20mM Tris-HCL (Sigma), 150 mM NaCl, pH7.5 
(Sigma).  
Detection of IgE anti Influenza 
Nitrocellulose membranes were then incubated 
with  serum  samples  (100  ul)  (diluted  in  2  ml 
TBS-Tween  20)  for  1  hr  at  room  temperature,  after 
which goat IgG fraction to human IgE (MP Biomedi-
cals, Solon, OH), diluted 1:20-40 in TBS-Tween 20 and Int. J. Med. Sci. 2011, 8 
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1% milk in TBS-Tween 20 (1 ml), was added to mem-
branes, and incubated overnight on a shaker at room 
temperature.  
Detection of anti Influenza IgG 
IgG  Fraction  goat  anti  human  IgG  (heavy  and 
light  chains  specific)  (ICN/Cappell,  West  Chester, 
PA), diluted 1:100 in TBS-Tween 20 and 1% milk in 
TBS-Tween  20  (1ml)  was added  to  membranes  and 
incubated for one hour on a shaker at room tempera-
ture. The membranes were then washed three times 
with TBS-Tween 20.  
For detection and development of both IgG and 
IgE  isotypes:  nitrocellulose  membranes  were  then 
incubated  with  rabbit  anti-goat  peroxidase  labeled 
antibody  (whole  molecule)  (Cappel,  West  Chester, 
PA), diluted 1:2000 in TBS-Tween 20 and 1% Milk for 
1 hour on a shaker, washed 3 times with TBS-Tween 
20, and then developed in TMB substrate solution (2 
ml).  The  membranes  were  then  removed  from  the 
TMB substrate solution, at which time they were read 
dried, and scanned (Gel Doc 2000 System with spe-
cific  The  Discovery  Series:  Quantity  One  software 
BioRad, Hercules, CA). 
Cytokine determination 
Serum cytokines [Interleukin-2 (IL-2), Interferon 
gamma  (IFN-γ),  Interleukin-4  (IL-4),  Interluekin-10 
(IL-10)]  were  determined  by  sandwich  ELISA  (Bio-
source, Camarillo, CA) according to the manufactur-
er’s protocol.  
Statistical Analysis 
Cytokine  determinations  from  vaccinated  and 
non vaccinated subjects were compared on each var-
iable. Significance between variables was determined 
using student’s t-tests. A p value of <0.05 was con-
sidered  statistically  significant  for  all  comparisons. 
The  degree  of  association  between  these  measures 
was assessed using Pearson’s correlations. Statistical 
analyses  were  performed  using  SPSS  for  Windows, 
version 10.0 software (SPSS Inc., Chicago, IL). 
RESULTS. 
1. Characteristics of Study Subjects  
Serum IgE levels and IgE and IgG anti-Influenza 
virus antibodies were studied in children (N=3) (m/f 
14-16  y/o)  and  adults  (N=3)  (m/f,  41-49  y/o)  ap-
proaching two years post  vaccination, as well as in 
non  infected,  non-vaccinated  children  (N=2)  (m/1 
y/o) (Table 1). 
2. Total IgE 
 Total  serum  IgE  levels  were  both  normal  and 
elevated in adults and children vaccinated  with In-
fluenza virus. Children with no history of either In-
fluenza virus infection or vaccination had serum IgE 
levels which were low (Table 1). 
3. Anti-Influenza Abs  
IgG.  Serum  obtained  from  subjects  who  were 
vaccinated  had  positive  dot  blots  for  IgG  an-
ti-Influenza  virus  antibodies  (Data  not  shown).  In 
contrast,  serum  from  non-infected,  non-vaccinated 
(control) subjects did not contain IgG anti-VZV anti-
bodies. 
IgE. Serum obtained from 5 out of 6 vaccinated 
subjects  (83%)  had  positive  dot  blots  for  IgE  an-
ti-Influenza virus antibodies; they had either elevated 
or normal levels of serum IgE (Table 1) (Fig 1, lanes 1, 
2).  In  contrast,  serum  from  non-infected,  non  vac-
cinated  subjects  did  not  contain  IgE  anti-Influenza 
virus antibodies (Fig 1, lane 3); they had low levels of 
serum IgE.  
TABLE 1. CHARACTERISTICS OF STUDY SUBJECTS AND SERUM IgE LEVELS 
Patient  Sex/Age (years)  Form of Influenza virus inocula-
tion (Fall 2009) 
Serum IgE levels 
(IU/ml) 
IgE  anti-  Influenza 
virus (+/-)# 
IgG  anti-Influenza  virus 
(+/-)# 
1  F (18)  Flumist®1  154*  +  + 
2  F (41)  Fluzone®2  15  +  + 
3  M (44)  Fluzone  232*  +  + 
4  M (14)  Flumist  34  +  + 
5  M (16)   Flumist**  132  -  + 
6  F(49)  Fluzone  34  +  + 
7  M (1)  None  14  -  - 
8  M(1)  None  15  -  - 
Patients were inoculataed with either 1Flumist® (live attenuated Influenza Virus Vaccine),  
 2 Fluzone® (inactivated Influenza Virus Vaccine) or none. *Patient skin test (skin prick) positive for food or environmental allergens. Refer-
ence range for healthy adult or child serum: IgE: 20-100 IU/mL.**Was given Flumist in 2008. 
# Immunoblot (See Material and Methods). 
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Figure 1. Immunoblot analysis of IgE anti-influenza virus antibodies. Serum from subjects with past history of 
influenza virus vaccination or no infection was incubated with nitrocellulose strips containing influenza virus vaccine antigen 
(see Materials and Methods). Lane 1: representative blot of subject vaccinated with influenza virus vaccine, who had elevated 
serum IgE levels (>100 IU/ml). Lane 2: representative blot of subject vaccinated with influenza virus vaccine who had low 
serum IgE levels (<100 IU/ml). Lane 3: control subject, no history of infection or vaccination. 
 
 
4. Cytokines in serum.  
Similar levels of IL-2, IFN-γ, IL-4, and IL-10 cy-
tokines  were  detected  in  serum  of  vaccinated  com-
pared with non vaccinated subjects (p>0.05), as well 
as  between  vaccinated  adults  compared  with  vac-
cinated children, compared with non vaccinated sub-
jects (p>0.05) (data not shown). 
DISCUSSION 
The present studies are the first to describe the 
long-term persistence of IgE anti-Influenza virus an-
tibodies in vaccinated children and adults, with nor-
mal  and  elevated  levels  of  serum  IgE,  approaching 
two years post vaccination. 
 Influenza  viruses  are  respiratory  pathogens 
which  belong  to  the  Orthomyxoviridae  family  [20], 
and  are  a  group  of  negative-stranded,  segmented 
RNA viruses [20]. Three types of influenza virus (A, B, 
C) have been reported which are categorized by their 
antigenic differences in the nucleoprotein and matrix 
protein  [21].  Influenza  A  and  B  viruses  commonly 
cause disease in humans [21]. The Influenza A virus 
has  surface  antigens,  but  diverse  subtype-specific, 
haemagglutinin  (HA)  and  neuraminidase  (NA);  an-
tibodies to these viral antigens mediate immunity to 
infection  [21].  When  an  influenza  virus  infection  is 
first experienced, an IgM response is elicited to both 
type and subtype-specific antigens of influenza virus 
[22]; subsequent infections or vaccinations later in life 
to  the  type-specific  antigens  would  be  restricted  to 
IgG responses [22]. 
Influenza virus causes annual epidemics, which 
generally occur in the winter months in the Northern 
hemisphere [21], and is spread from person to person 
by either direct contact with a virus infected individ-
ual, or by virus droplets from sneezing or coughing 
[21]. An uncomplicated case of influenza will resolve 
within  1-2  weeks;  however,  in  patients  with  other 
underlying  medical conditions, infection with influ-
enza may result in hospitalization and death [21].It 
has been reported that influenza has been responsible 
for high numbers of morbidity and mortality in the 
United States [23]. All age groups can be infected with 
Influenza virus, but children have the highest infec-
tion  rates  [24].  In  the  United  States,  vaccination  is 
recommended for people with increased rate of med-
ical conditions (50-64 y/o), and for children 6 months 
and older [21, 25]. In some countries, vaccination is 
recommended for health care workers, and caregivers 
in nursing homes and assisted living facilities [21].  
It is well known that both humoral (mucosal and 
serum  antibody  responses),  as  well  as  cellular  im-
mune responses play a role in resistance to influenza 
infection [26-29]. sIgA, as well as IgM are the neutral-
izing antibodies in the mucosa that prevent virus en-
try and inhibit virus replication [30]. During primary 
infection, IgG, IgA and IgM- specific to HA have been 
detected  in  nasal  washings  by  enzyme-linked  im-
munosorbent assay, although IgA and IgM were more 
frequently detected than IgG [30]; IgE-specific to HA 
was  not  studied.  Natural  wild  type  Influenza  virus 
infection  can  stimulate  a  local  IgA  response,  which 
can  last  3-5  months,  as  well  as  influenza-specific 
IgA-committed memory cells [30]. Levels of neutral-
izing antibodies induced by live virus vaccine corre-
late with resistance to infection after challenge with 
wild-type  virus  [28].  Previous  studies  by  others  re-
ported that during primary infection, IgG, IgA, and 
IgM  can  be  detected  within  10-14  days  [30].  Two 
weeks post infection, levels of IgA and IgM peak, and 
then begin to decline, whereas four to six weeks post 
infection, levels of IgG peak [30]. In the primary re-
sponse IgG and IgM are dominant, and after second-Int. J. Med. Sci. 2011, 8 
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ary infection, IgG and IgA are the predominant im-
munoglobulin isotypes detected in serum [21, 30].  
It has been reported that in vaccinated individu-
als,  2-6  days  post  vaccination,  serum  antibody  re-
sponses  to  trivalent  (inactivated)  influenza  vaccine 
were  detected,  peaked  2-3  weeks  post  vaccination, 
and then was two-fold lower 6 moths post vaccination 
[31];  influenza  specific  IgG1  antibodies  were  the 
dominant antibody detected, as well as lower levels of 
IgM and IgA [31]; IgE antibodies were not studied. It 
should be mentioned that in the United States, mu-
cosal  vaccines  for  Influenza  are  now  available  for 
children, and target the mucosa and lymphoid tissue, 
which are areas where early infection occurs [32]. In 
other investigations, it has been shown that influenza 
virus-specific  antibodies  in  saliva  consist  of  SIgA1, 
which is first detected 5-7 days after vaccination, and 
the elevated antibody response lasts for 3-5 days [19, 
31]. However, an increase of H1N1 and B strains in-
fluenza virus antibodies has been found in oral fluid 7 
days  post  vaccination  [18].  Levels  of  influenza  vi-
rus-specific ASCs in blood is low before vaccination, 
compared with levels in tonsils and nasal mucosa [18]; 
after  vaccination,  this  level  increased  nearly  4  log10 
[18]. Live, attenuated influenza vaccines induce both 
mucosal  and  systemic  responses  [21].  The 
cold-adapted  (CA)  live,  attenuated  vaccines  are  ad-
ministered intranasally in children and provide pro-
tective  immunity  [21].  After  CA  vaccination,  serum 
antibody responses and/or virus shedding has been 
noted in most recipients [21].  
In the present study, vaccinated adult (live at-
tenuated  vaccine)  and  pediatric  (nasal  vaccine)  pa-
tients (2-20 months post vaccination), with both nor-
mal and elevated serum IgE levels, had specific IgG 
and  IgE  anti-influenza  antibodies,  detected  by  im-
munoblot.  Of  notable  interest  under  study,  is  the 
long-term persistence of these antibodies (approach-
ing two years post vaccination). Although prior liter-
ature suggests that Influenza virus specific IgG anti-
bodies wane 6 months post vaccination [31], we were 
able to detect both IgG and IgE specific Influenza vi-
rus antibodies up to two years post vaccination. It is 
conceivable that the detection of IgG and IgE reported 
here (dot blot technology) affords a greater level of 
sensitivity  than  previous  reports  which  employ 
ELISA based approaches. In this manner our data are 
consistent  with  the  detection  of  other  reports  with 
respect  to  immunoglobulin  anti-influenza  presence. 
However, in our studies, the levels of Ig anti-influenza 
antibodies over time were not determined.  
Given  the  findings  of  this  study,  the  presence 
and  persistence  of  IgG  and  IgE  anti-influenza  anti-
bodies in the serum from those with normal and ele-
vated levels of IgE are understandable. Our findings 
appear to be of importance and relevant because pre-
viously  described  studies  from  our  laboratory  [33] 
have shown the presence of IgE anti-cancer antibodies 
present in patients with both normal and elevated IgE 
levels which were able to mediate antibody depend-
ent cell mediated cytotoxicity against cancer cells in 
vitro. These responses were not correlated with total 
serum IgE levels. We therefore speculate that it is not 
the total IgE levels that are important but rather the 
fraction of IgE anti-influenza antibodies as a percent-
age of the total IgE pool that are responsible for me-
diating any effects. Our discovery also suggests that 
the IgE molecule has evolved to serve various benefi-
cial functions, including anti-viral. However, at pre-
sent,  it  is  unclear  how  IgE  promotes  its  activity  in 
these viruses.  
Although  IgE  anti-viral  responses  are  demon-
strated,  the  limitations  of  this  study  include  small 
sample size, and the lack of racial disparity. All the 
subjects were Caucasian and in good health. It could 
be that the immunoglobulin anti-viral responses may 
differ in vaccinated subjects of African American or 
Hispanic descent as has been shown in other vaccine 
trials (34). Additional studies towards understanding 
immunoglobulin anti-viral responses in subjects and 
patients with co-morbidities or immunocompromise 
are warranted. 
The  results  presented  here  suggest  that  IgE  is 
associated  with  anti-influenza  immunity  and  their 
memory responses. Further studies are necessary to 
elucidate  the  role  of  immunoglobulins  in  influenza 
infection and to determine possible functional roles of 
IgE in this disease and its relationship to viral patho-
physiology. 
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